Skip to main content
. 2020 Feb 7;10:2083. doi: 10.1038/s41598-020-58674-4

Figure 2.

Figure 2

Forest plot of the meta-analysis for estimating the HR and 95% CIs for OS (A) and PFS (B) in the intervention group, compared with that in the control group (OS: HR: 0.76; 95% CI, 0.71–0.82, P = 0.000; PFS: HR: 0.81; 95% CI, 0.73–0.89, P = 0.000). Squares indicate study-specific HRs. Horizontal lines crossing the square indicate the 95% CIs. The dashed vertical lines indicate the specific pooled HR. Diamonds indicate the estimated overall effect according to meta-analysis random effect of pooled HRs from all included studies with their corresponding 95% CIs. Favours intervention shows that anti-PD-1/PD-L1 inhibitors (Atezolizumab, Pembrolizumab, Nivolumab, Avelumab or Durvalumab) had survival benefit over the control therapies (placebo, chemotherapy, targeted therapy alone or their combination); Favours control shows that the control therapies had survival benefit over anti-PD-1/PD-L1 inhibitors. Herbst 2016-2 mg/kg, 2 mg/kg subset in Herbst 2016; Herbst 2016-10 mg/kg, 10 mg/kg subset in Herbst 2016; Eng-C 2019, combined therapy subset in Eng 2019; Eng-M 2019, monotherapy subset in Eng 2019; Hamid 2017-2 mg/kg, 2 mg/kg subset in Hamid 2017; Hamid 2017-10 mg/kg, 10 mg/kg subset in Hamid 2017.